drugset / Trial / NCT03426540

Intravitreal Conbercept After Vitrectomy

NCT03426540

Phase 0 Completed 50 enrolled Tianjin Medical University Eye Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate the safety and efficacy of intravitreal conbercept after vitrectomy for the management of early-stage proliferative diabetic retinopathy (PDR). Hypothesis: intravitreal conbercept therapy may promote functional and anatomic recovery from PDR. intravitreal conbercept therapy may be a useful and safe method for improving visual outcomes of surgery for early-stage PDR.

Timeline

Start
2017-01-01
Primary completion
2018-03-30
Completion
2019-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Conbercept Protein / enzyme biologic 0.5 mg Intravitreal